Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

So far, so good
January 2020
SHARING OPTIONS:

TEL AVIV, Israel—BioLineRx Ltd. recently announced that preliminary data from its Phase 2a COMBAT/KEYNOTE-202 study showed that a combination regimen of BL-8040, Keytruda and chemotherapy produced high response and disease control rates in metastatic pancreatic cancer patients. BL-8040 is an inhibitor of the CXCR4 chemokine receptor, which plays a role in tumor growth, metastasis, angiogenesis and therapeutic resistance. Of 15 evaluable patients, four showed a partial response by the data cutoff date of Sept. 30, with eight patients presenting with stable disease. Median progression-free survival and overall survival were not yet reached by the cutoff date, and the combination regimen was generally well tolerated; 15 serious adverse events were reported, and two patients discontinued the study. The data were presented at ESMO IO 2019.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.